GlassScriptPhysician profile
Jaime F Roman
NPI 1144394784
$5,112.83
in general payments reported to CMS, 2019-2025
23 companies · $1,951 in 2025
The $1,951 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $111 · 2021: $14.09 · 2022: $739 · 2023: $738 · 2024: $1,310 · 2025: $1,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,965 · Education: $35.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,964.66 |
| Education | $35.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,767.35 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $747.51 | 2022-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $475.68 | 2022-2025 | Ozempic, Rybelsus |
| Ardelyx, INC. | $374.99 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $225.62 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $205.03 | 2023-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $163.38 | 2019-2023 | Seglentis, Livalo |
| Radius Health, INC. | $158.57 | 2019 | |
| Intra-Sana Laboratories | $140.38 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.55 | 2022-2024 | Xifaxan, Trulance |
| Intuity Medical INC | $112.54 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Exact Sciences Corporation | $104.29 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $87.96 | 2022 | |
| Novartis Pharmaceuticals Corporation | $79.82 | 2024 | |
| Gilead Sciences, INC. | $67.61 | 2025 | Trodelvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $54.88 | 2025 | Myfembree, Gemtesa |
| Biogen, INC. | $39.73 | 2025 | Skyclarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.71 | 2024-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $35.44 | 2023-2024 | Rayaldee |
| Amarin Pharma, INC. | $27.54 | 2020-2021 | |
| Calliditas Therapeutics US INC. | $26.18 | 2025 | Tarpeyo |
| Pfizer INC. | $24.38 | 2025 | |
| Emd Serono, INC. | $16.69 | 2023 | Bavencio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.